MiMedx Group Inc MDXG:NASDAQ

Last Price$3.70Cboe Real-Time Last Sale as of 9:48AM ET 6/27/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change-0.13(3.39%)
Bid (Size)$3.69 (196)
Ask (Size)$3.72 (200)
Day Low / High$3.83 - 3.91
Volume19.8 K

View Biotechnology IndustryPeer Comparison as of 06/27/2022


MiMedx Group Inc ( NASDAQ )

Price: $3.70
Change: -0.13 (3.39%)
Volume: 19.8 K
9:48AM ET 6/27/2022

Protagonist Therapeutics Inc ( NASDAQ )

Price: $9.02
Change: -0.06 (0.66%)
Volume: 15.7 K
9:46AM ET 6/27/2022

Altimmune Inc ( NASDAQ )

Price: $9.83
Change: -0.46 (4.47%)
Volume: 40.3 K
9:49AM ET 6/27/2022

Bionano Genomics Inc ( NASDAQ )

Price: $1.52
Change: -0.11 (6.48%)
Volume: 227.6 K
9:48AM ET 6/27/2022

Kodiak Sciences Inc ( NASDAQ )

Price: $8.67
Change: -0.37 (4.09%)
Volume: 11.6 K
9:50AM ET 6/27/2022

Read more news Recent News

MiMedx Says Glass Lewis Recommends in Favor of Director Nominees, Say-on-Pay Proposal
10:14AM ET 5/20/2022 MT Newswires

MiMedx Group (MDXG) said Friday that proxy advisory firm Glass Lewis has recommended that shareholders vote for the re-election of its two director...

-- Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $58.9M, vs. Street Est of $54.1M
4:34PM ET 5/03/2022 MT Newswires


MiMedx Group to Launch Exclusive Version of WoundGenex's Premier Graft Program in US; Shares Gain
10:30AM ET 3/16/2022 MT Newswires

MiMedx Group (MDXG) has entered a partnership to launch an exclusive version of wound care management firm WoundGenex's Premier Graft Program for its...

MiMedx Group Swings to Q4 Income, Revenue Declines
5:09PM ET 2/28/2022 MT Newswires

MiMedx Group (MDXG) on Monday reported Q4 earnings of $0.01 per diluted share, compared with a loss of $0.17 a year ago. Analysts polled by Capital IQ also...

Company Profile

Business DescriptionMiMedx Group, Inc. is a therapeutic biologics company, which engages in the design, manufacture, and marketing of products, and tissue processing services. It serves the wound care, burn, surgical, orthopedic, spine, sports medicine, ophthalmic, and dental sectors of healthcare. Its biomaterial platform technologies include AmnioFix and EpiFix, a tissue allografts derived from amnion and chorion layers of human placental membrane, EpiCord and AmnioCord, a tissue allografts derived from umbilical cord tissue, and AmnioFill, a placental connective tissue matrix derived from the placental disc and other placental tissue. The company was founded on July 30, 1985 and is headquartered in Marietta, GA. View company web site for more details
Address1775 West Oak Commons Court NE
Marietta, Georgia 30062
Number of Employees690
Recent SEC Filing06/17/2022S-8
Chief Executive Officer & DirectorTimothy R. Wright
Senior Vice President-Operations & ProcurementScott M. Turner
Chief Financial OfficerPeter M. Carlson
Chief Medical OfficerDavid H. Mason

Company Highlights

Price Open$3.85
Previous Close$3.83
52 Week Range$3.04 - 15.99
Market Capitalization$419.4 M
Shares Outstanding113.4 M
SectorHealth Technology
Next Earnings Announcement08/02/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.17
Beta vs. S&P 500N/A
Revenue$245.0 M
Net Profit Margin-4.81%
Return on Equity-14.18%

Analyst Ratings as of 07/23/2021

Consensus RecommendationConsensus Icon
Powered by Factset